Roche Diagnostics and Exiquon have announced an amendment to their 2005 license and distribution agreement for the Universal Probelibrary.
The Universal Probelibrary is based on Exiqon's proprietary locked nucleic acid (LNA) oligonucleotides.
Under the terms of the agreement, Roche's exclusive rights to sell and distribute the Probelibrary products are extended on a co-exclusive basis.
In addition, Roche obtains co-exclusive rights to use the Universal Probelibrary for the development and manufacturing of its Realtime ready quantitative PCR assays.
With the Realtime ready assay line, Roche Applied Science will offer a customisable portfolio of validated target-specific gene expression assays for quantitative PCR in single assay format and multiwell plate format, pre-plated in 96- and 384-well quantitative PCR plates for the Lightcycler System.
